Specific treatment1. If GVHD+NS • Immunosuppression (CNI, rituximab, glucocorticoids, MMF)2. MN • PLA2R antibody negative+FAT1 positive → rituximab • PLA2 antibody positive → rituximab (similar to patients with primary MN) • Glucocorticoids (mild response)3. Minimal change disease • Oral glucocorticoids (as for primary minimal change disease, according to KDIGO guidelines) • Other suggestions: rituximab, CNI. The gene discussed is PLA2R1; the disease is graft versus host disease.